6.35
price up icon0.32%   0.02
 
loading
Precedente Chiudi:
$6.33
Aprire:
$6.34
Volume 24 ore:
2.84M
Relative Volume:
0.56
Capitalizzazione di mercato:
$1.65B
Reddito:
$6.22B
Utile/perdita netta:
$187.00M
Rapporto P/E:
8.8613
EPS:
0.7166
Flusso di cassa netto:
$508.00M
1 W Prestazione:
-3.20%
1M Prestazione:
-14.07%
6M Prestazione:
-40.38%
1 anno Prestazione:
-57.55%
Intervallo 1D:
Value
$6.32
$6.4782
Intervallo di 1 settimana:
Value
$6.2745
$6.62
Portata 52W:
Value
$6.18
$15.88

Organon Co Stock (OGN) Company Profile

Name
Nome
Organon Co
Name
Telefono
551-430-6000
Name
Indirizzo
30 HUDSON STREET, JERSEY CITY
Name
Dipendente
10,000
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
OGN's Discussions on Twitter

Compare OGN vs LLY, JNJ, ABBV, AZN, NVS

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
OGN
Organon Co
6.35 1.65B 6.22B 187.00M 508.00M 0.7166
Drug Manufacturers - General icon
LLY
Lilly Eli Co
985.08 879.67B 65.18B 20.64B 5.96B 22.59
Drug Manufacturers - General icon
JNJ
Johnson Johnson
241.52 582.04B 94.19B 26.80B 19.70B 11.05
Drug Manufacturers - General icon
ABBV
Abbvie Inc
219.68 388.43B 61.16B 4.19B 17.82B 2.3614
Drug Manufacturers - General icon
AZN
Astrazeneca Plc
189.90 294.50B 58.80B 10.24B 8.98B 3.2788
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
153.44 292.79B 54.72B 14.02B 15.32B 7.1855

Organon Co Stock (OGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-12-09 Iniziato Barclays Underweight
2025-10-27 Downgrade Piper Sandler Overweight → Underweight
2025-05-02 Downgrade Evercore ISI Outperform → In-line
2024-09-06 Downgrade JP Morgan Neutral → Underweight
2023-11-03 Downgrade Goldman Buy → Neutral
2023-09-21 Iniziato Barclays Overweight
2023-03-16 Iniziato Raymond James Outperform
2022-10-14 Downgrade BofA Securities Neutral → Underperform
2022-09-06 Aggiornamento Piper Sandler Neutral → Overweight
2022-08-05 Downgrade BofA Securities Buy → Neutral
2022-04-27 Iniziato Goldman Buy
2022-04-06 Ripresa Morgan Stanley Equal-Weight
2021-10-07 Iniziato Piper Sandler Neutral
2021-09-01 Iniziato BofA Securities Buy
2021-07-22 Iniziato Citigroup Buy
2021-06-15 Iniziato JP Morgan Neutral
2021-06-11 Iniziato Morgan Stanley Equal-Weight
2021-06-10 Iniziato Evercore ISI Outperform
Mostra tutto

Organon Co Borsa (OGN) Ultime notizie

pulisher
Mar 13, 2026

Organon & Co. Experiences Evaluation Revision Amidst Market Challenges and Performance Divergence - Markets Mojo

Mar 13, 2026
pulisher
Mar 12, 2026

OGN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Mar 12, 2026
pulisher
Mar 12, 2026

Organon Q4 2025 slides: Revenue declines accelerate, stock tumbles on earnings miss - Investing.com Nigeria

Mar 12, 2026
pulisher
Mar 11, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Organon & Co. (OGN) And Encourages Shareholders to Reach Out - ACCESS Newswire

Mar 11, 2026
pulisher
Mar 10, 2026

Organon trades in red for seven straight sessions - MSN

Mar 10, 2026
pulisher
Mar 09, 2026

(OGN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Mar 09, 2026
pulisher
Mar 07, 2026

Organon Q3 Net Margin Squeeze Challenges Bullish Earnings Growth Narratives - Sahm

Mar 07, 2026
pulisher
Mar 07, 2026

Organon rises after update on independent review - MSN

Mar 07, 2026
pulisher
Mar 07, 2026

Organon outlines flat $6.2B revenue and $1.9B EBITDA targets for 2026 as cost controls and portfolio shifts take center stage - MSN

Mar 07, 2026
pulisher
Mar 07, 2026

Royce & Associates LP Trims Position in Organon & Co. $OGN - MarketBeat

Mar 07, 2026
pulisher
Mar 06, 2026

Organon climbs 6% after audit clears company of wrongdoing - MSN

Mar 06, 2026
pulisher
Mar 05, 2026

Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Mar 05, 2026
pulisher
Mar 04, 2026

Organon & Co. Hits Day Low of $7.50 Amid Price Pressure - Markets Mojo

Mar 04, 2026
pulisher
Mar 03, 2026

Organon (OGN) HR chief gets stock awards, withholds shares for taxes - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Organon & Co. (NYSE:OGN) Short Interest Up 21.9% in February - MarketBeat

Mar 03, 2026
pulisher
Mar 03, 2026

Organon (OGN) CFO granted shares, withholds stock to pay taxes - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Organon (OGN) executive reports PSU share awards and tax withholding - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Organon (OGN) CIO logs stock awards and tax withholding share disposals - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Organon (OGN) GC Weaver gets stock awards, shares withheld for tax - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Organon (NYSE: OGN) interim CEO reports stock awards and tax share offsets - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Can VTAMA’s Pediatric Sleep Data Nudge Organon (OGN) Toward a Stronger Dermatology-Led Growth Identity? - simplywall.st

Mar 03, 2026
pulisher
Mar 03, 2026

Organon & Co. (OGN) Stock Analysis: Key Insights On Its 25.17% Potential Upside - DirectorsTalk Interviews

Mar 03, 2026
pulisher
Mar 03, 2026

KDventures AB Announces Organon Discontinues Development of Forendo's Drug Candidate for Polycystic Ovarian Syndrome - marketscreener.com

Mar 03, 2026
pulisher
Mar 03, 2026

KDventures meddelar att Organon har avbrutit utvecklingen av det tidigare portföljbolaget Forendos läkemedelskandidat mot PCOS - GlobeNewswire Inc.

Mar 03, 2026
pulisher
Mar 02, 2026

Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages - MarketBeat

Mar 02, 2026
pulisher
Mar 01, 2026

OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis - Bitget

Mar 01, 2026
pulisher
Mar 01, 2026

Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Mar 01, 2026
pulisher
Mar 01, 2026

Is Organon (OGN) Pricing Reflect Its Value After Reported Sun Pharma Takeover Interest - Yahoo Finance

Mar 01, 2026
pulisher
Feb 28, 2026

OGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 28, 2026
pulisher
Feb 27, 2026

Organon presents sleep improvement data for VTAMA cream in children By Investing.com - Investing.com Australia

Feb 27, 2026
pulisher
Feb 27, 2026

Assessing Organon (OGN) Valuation After VTAMA Sleep Outcome Data From Phase 3 ADORING Trials - simplywall.st

Feb 27, 2026
pulisher
Feb 27, 2026

Organon presents sleep improvement data for VTAMA cream in children - Investing.com

Feb 27, 2026
pulisher
Feb 27, 2026

Vanguard Group Inc. Has $383.72 Million Position in Organon & Co. $OGN - MarketBeat

Feb 27, 2026
pulisher
Feb 26, 2026

Organon Refocuses On Contraception With MIUDELLA Deal And JADA Exit - Sahm

Feb 26, 2026
pulisher
Feb 26, 2026

Organon & Co. Confronts Mounting Global Pricing Pressure as Health Reforms Threaten Margin Stability and Nexplanon Growth - TipRanks

Feb 26, 2026
pulisher
Feb 25, 2026

Organon & Co. (NYSE:OGN) Trading Down 6.3%Time to Sell? - MarketBeat

Feb 25, 2026
pulisher
Feb 25, 2026

Organon & Co. (OGN) Stock Analysis: Navigating a Potential Upside Amidst a Challenging Landscape - DirectorsTalk Interviews

Feb 25, 2026
pulisher
Feb 25, 2026

Decoding Organon & Co (OGN): A Strategic SWOT Insight - GuruFocus

Feb 25, 2026
pulisher
Feb 24, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Feb 24, 2026
pulisher
Feb 24, 2026

Organon & Co. (NYSE:OGN) Price Target Raised to $8.00 at Barclays - MarketBeat

Feb 24, 2026
pulisher
Feb 24, 2026

Organon price target raised to $8 from $7.50 at Barclays - TipRanks

Feb 24, 2026
pulisher
Feb 24, 2026

Organon licenses hormone-free copper IUD from Sebela Pharmaceuticals By Investing.com - Investing.com India

Feb 24, 2026
pulisher
Feb 23, 2026

Organon & Co. (OGN) posts FY adjusted EPS of $3.66, EBITDA margin at 30.7% - MSN

Feb 23, 2026
pulisher
Feb 23, 2026

Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66, EBITDA Margin at 30.7% - Insider Monkey

Feb 23, 2026
pulisher
Feb 23, 2026

Organon stock jumps in premarket after MIUDELLA licensing deal, with 10-K filing in focus - TechStock²

Feb 23, 2026
pulisher
Feb 23, 2026

Organon Signs Deal for Global Rights to Sebela's Miudella Intrauterine Device - marketscreener.com

Feb 23, 2026
pulisher
Feb 23, 2026

Organon licenses hormone-free copper IUD from Sebela Pharmaceuticals - Investing.com

Feb 23, 2026
pulisher
Feb 23, 2026

Organon Licenses MIUDELLA® to Enhance Women's Health Commitment - Intellectia AI

Feb 23, 2026
pulisher
Feb 23, 2026

Organon enters into agreement to license Miudella® - marketscreener.com

Feb 23, 2026
pulisher
Feb 23, 2026

First hormone-free copper IUD in 40 years lands $27.5M Organon deal - Stock Titan

Feb 23, 2026
pulisher
Feb 22, 2026

Organon (OGN) Is Up 9.6% After Weaker 2025 Earnings And New 2026 Revenue GuidanceWhat's Changed - simplywall.st

Feb 22, 2026

Organon Co Azioni (OGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general PFE
$26.58
price down icon 1.04%
drug_manufacturers_general NVO
$37.96
price down icon 0.16%
$144.99
price down icon 0.15%
$366.21
price down icon 0.43%
drug_manufacturers_general MRK
$115.61
price down icon 0.26%
drug_manufacturers_general NVS
$153.44
price down icon 0.53%
Capitalizzazione:     |  Volume (24 ore):